{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:44:28Z","timestamp":1793745868914,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41582-023-00802-5","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T10:03:54Z","timestamp":1683194634000},"page":"333-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["The noradrenergic subtype of Parkinson disease: from animal models to clinical practice"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-0505","authenticated-orcid":false,"given":"K.","family":"Ray Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7540","authenticated-orcid":false,"given":"Valentina","family":"Leta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"802_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435\u2013450 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"802_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mds.23795","volume":"27","author":"KA Jellinger","year":"2012","unstructured":"Jellinger, K. A. Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Mov. Disord. 27, 8\u201330 (2012).","journal-title":"Mov. Disord."},{"key":"802_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jnnp.52.Suppl.18","volume":"52","author":"DB Calne","year":"1989","unstructured":"Calne, D. B. Is \u201cParkinson\u2019s disease\u201d one disease? J. Neurol. Neurosurg. Psychiatry 52, 18\u201321 (1989).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"802_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/archneur.65.6.705","volume":"65","author":"WJ Weiner","year":"2008","unstructured":"Weiner, W. J. There is no Parkinson disease. Arch. Neurol. 65, 705\u2013708 (2008).","journal-title":"Arch. Neurol."},{"key":"802_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson\u2019s: a syndrome rather than a disease? J. Neural Transm. 124, 907\u2013914 (2017).","journal-title":"J. Neural Transm."},{"key":"802_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ana.20834","volume":"59","author":"JW Langston","year":"2006","unstructured":"Langston, J. W. The Parkinson\u2019s complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591\u2013596 (2006).","journal-title":"Ann. Neurol."},{"key":"802_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nan.12297","volume":"42","author":"A Bellucci","year":"2016","unstructured":"Bellucci, A. et al. Review: Parkinson\u2019s disease: from synaptic loss to connectome dysfunction. Neuropathol. Appl. Neurobiol. 42, 77\u201394 (2016).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"802_CR9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg, D. et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 30, 1600\u20131611 (2015).","journal-title":"Mov. Disord."},{"key":"802_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/mds.27691","volume":"34","author":"KR Chaudhuri","year":"2019","unstructured":"Chaudhuri, K. R., Jenner, P. & Antonini, A. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson\u2019s disease? Mov. Disord. 34, 816\u2013819 (2019).","journal-title":"Mov. Disord."},{"key":"802_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi, K. et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease \u2013 an evidence-based medicine review. Mov. Disord. 34, 180\u2013198 (2019).","journal-title":"Mov. Disord."},{"key":"802_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"802_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mds.26510","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson\u2019s disease subtypes. Mov. Disord. 31, 1095\u20131102 (2016).","journal-title":"Mov. Disord."},{"key":"802_CR14","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/mds.23305","volume":"25","author":"AE Kingsbury","year":"2010","unstructured":"Kingsbury, A. E. et al. Brain stem pathology in Parkinson\u2019s disease: an evaluation of the Braak staging model. Mov. Disord. 25, 2508\u20132515 (2010).","journal-title":"Mov. Disord."},{"key":"802_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SS Ahmed","year":"2009","unstructured":"Ahmed, S. S., Santosh, W., Kumar, S. & Christlet, H. T. Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16, 63 (2009).","journal-title":"J. Biomed. Sci."},{"key":"802_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","volume":"84","author":"C Marras","year":"2013","unstructured":"Marras, C. & Lang, A. Parkinson\u2019s disease subtypes: lost in translation. J. Neurol. Neurosurg. Psychiatry 84, 409\u2013415 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"802_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic, J. & Tan, E. K. Parkinson\u2019s disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 91, 795\u2013808 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"802_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2017.09.033","volume":"1702","author":"DS Goldstein","year":"2019","unstructured":"Goldstein, D. S. & Sharabi, Y. The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Res. 1702, 74\u201384 (2019).","journal-title":"Brain Res."},{"key":"802_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","volume":"18","author":"DS Goldstein","year":"2011","unstructured":"Goldstein, D. S. et al. Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 18, 703\u2013710 (2011).","journal-title":"Eur. J. Neurol."},{"key":"802_CR20","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","volume":"22","author":"A Sauerbier","year":"2016","unstructured":"Sauerbier, A., Jenner, P., Todorova, A. & Chaudhuri, K. R. Non motor subtypes and Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22, S41\u2013S46 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"802_CR21","first-page":"1775","volume":"46","author":"DN Tipre","year":"2005","unstructured":"Tipre, D. N. & Goldstein, D. S. Cardiac and extracardiac sympathetic denervation in Parkinson\u2019s disease with orthostatic hypotension and in pure autonomic failure. J. Nucl. Med. 46, 1775\u20131781 (2005).","journal-title":"J. Nucl. Med."},{"key":"802_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol. 21, 381\u2013392 (2022).","journal-title":"Lancet Neurol."},{"key":"802_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2967\/jnumed.117.190975","volume":"59","author":"A Nahimi","year":"2018","unstructured":"Nahimi, A. et al. Noradrenergic deficits in Parkinson disease imaged with 11C-MeNER. J. Nucl. Med. 59, 659\u2013664 (2018).","journal-title":"J. Nucl. Med."},{"key":"802_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128, 1314\u20131322 (2005).","journal-title":"Brain"},{"key":"802_CR25","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/brain\/awq268","volume":"133","author":"N Pavese","year":"2010","unstructured":"Pavese, N., Metta, V., Bose, S. K., Chaudhuri, K. R. & Brooks, D. J. Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction. Brain 133, 3434\u20133443 (2010).","journal-title":"Brain"},{"key":"802_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/mdc3.13319","volume":"8","author":"J Pasquini","year":"2021","unstructured":"Pasquini, J., Brooks, D. J. & Pavese, N. The cholinergic brain in Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 8, 1012\u20131026 (2021).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"802_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","volume":"18","author":"H Wilson","year":"2018","unstructured":"Wilson, H., Giordano, B., Turkheimer, F. E., Chaudhuri, K. R. & Politis, M. Serotonergic dysregulation is linked to sleep problems in Parkinson\u2019s disease. Neuroimage Clin. 18, 630\u2013637 (2018).","journal-title":"Neuroimage Clin."},{"key":"802_CR28","doi-asserted-by":"publisher","first-page":"e70244","DOI":"10.1371\/journal.pone.0070244","volume":"8","author":"R Erro","year":"2013","unstructured":"Erro, R. et al. The heterogeneity of early Parkinson\u2019s disease: a cluster analysis on newly diagnosed untreated patients. PLoS ONE 8, e70244 (2013).","journal-title":"PLoS ONE"},{"key":"802_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fnagi.2017.00301","volume":"9","author":"J Mu","year":"2017","unstructured":"Mu, J. et al. Parkinson\u2019s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front. Aging Neurosci. 9, 301 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"802_CR30","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay, A. J., LeWitt, P. A. & Kaufmann, H. Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov. Disord. 29, 1710\u20131719 (2014).","journal-title":"Mov. Disord."},{"key":"802_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/mds.27027","volume":"32","author":"N Titova","year":"2017","unstructured":"Titova, N. & Chaudhuri, K. R. Personalized medicine in Parkinson\u2019s disease: time to be precise. Mov. Disord. 32, 1147\u20131154 (2017).","journal-title":"Mov. Disord."},{"key":"802_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080773","author":"V Leta","year":"2021","unstructured":"Leta, V. et al. Personalised advanced therapies in Parkinson\u2019s disease: the role of non-motor symptoms profile. J. Pers. Med. https:\/\/doi.org\/10.3390\/jpm11080773 (2021).","journal-title":"J. Pers. Med."},{"key":"802_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s13311-020-00894-7","volume":"17","author":"C Marras","year":"2020","unstructured":"Marras, C., Chaudhuri, K. R., Titova, N. & Mestre, T. A. Therapy of Parkinson\u2019s disease subtypes. Neurotherapeutics 17, 1366\u20131377 (2020).","journal-title":"Neurotherapeutics"},{"key":"802_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland, J. C., Williams-Gray, C. H. & Barker, R. A. The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur. J. Neurosci. 49, 328\u2013338 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"802_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3233\/JPD-202088","volume":"10","author":"P Ghosh","year":"2020","unstructured":"Ghosh, P. et al. A dual centre study of pain in Parkinson\u2019s disease and its relationship with other non-motor symptoms. J. Parkinsons Dis. 10, 1817\u20131825 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"802_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF02984609","volume":"19","author":"H Matsui","year":"2005","unstructured":"Matsui, H. et al. Metaiodobenzylguanidine (MIBG) uptake in Parkinson\u2019s disease also decreases at thyroid. Ann. Nucl. Med. 19, 225\u2013229 (2005).","journal-title":"Ann. Nucl. Med."},{"key":"802_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00441-017-2649-1","volume":"373","author":"EE Benarroch","year":"2018","unstructured":"Benarroch, E. E. Locus coeruleus. Cell Tissue Res. 373, 221\u2013232 (2018).","journal-title":"Cell Tissue Res."},{"key":"802_CR38","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1474-4422(16)30048-5","volume":"15","author":"J Blesa","year":"2016","unstructured":"Blesa, J., Trigo-Damas, I. & Obeso, J. A. Parkinson\u2019s disease and thalamus: facts and fancy. Lancet Neurol. 15, e2 (2016).","journal-title":"Lancet Neurol."},{"key":"802_CR39","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/mds.25109","volume":"27","author":"C Pifl","year":"2012","unstructured":"Pifl, C., Kish, S. J. & Hornykiewicz, O. Thalamic noradrenaline in Parkinson\u2019s disease: deficits suggest role in motor and non-motor symptoms. Mov. Disord. 27, 1618\u20131624 (2012).","journal-title":"Mov. Disord."},{"key":"802_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.neuron.2019.05.034","volume":"103","author":"V Zerbi","year":"2019","unstructured":"Zerbi, V. et al. Rapid reconfiguration of the functional connectome after chemogenetic locus coeruleus activation. Neuron 103, 702\u2013718.e5 (2019).","journal-title":"Neuron"},{"key":"802_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1523\/JNEUROSCI.1647-17.2017","volume":"38","author":"EP Mills","year":"2018","unstructured":"Mills, E. P. et al. Brainstem pain-control circuitry connectivity in chronic neuropathic pain. J. Neurosci. 38, 465\u2013473 (2018).","journal-title":"J. Neurosci."},{"key":"802_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fncir.2018.00051","volume":"12","author":"SN Jacob","year":"2018","unstructured":"Jacob, S. N. & Nienborg, H. Monoaminergic neuromodulation of sensory processing. Front. Neural Circuits 12, 51 (2018).","journal-title":"Front. Neural Circuits"},{"key":"802_CR43","first-page":"121","volume":"46","author":"DB Bylund","year":"1994","unstructured":"Bylund, D. B. et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46, 121\u2013136 (1994).","journal-title":"Pharmacol. Rev."},{"key":"802_CR44","first-page":"267","volume":"47","author":"JP Hieble","year":"1995","unstructured":"Hieble, J. P. et al. International Union of Pharmacology. X. Recommendation for nomenclature of \u03b11-adrenoceptors: consensus update. Pharmacol. Rev. 47, 267\u2013270 (1995).","journal-title":"Pharmacol. Rev."},{"key":"802_CR45","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1358\/dof.2004.029.12.855246","volume":"29","author":"J Zhou","year":"2004","unstructured":"Zhou, J. Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29, 1235\u20131244 (2004).","journal-title":"Drugs Future"},{"key":"802_CR46","unstructured":"Abosamak, N. R. & Shahin, M. H. Beta 2 Receptor Agonists\/Antagonists (StatPearls, 2023)."},{"key":"802_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.410320510","volume":"32","author":"DC German","year":"1992","unstructured":"German, D. C. et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32, 667\u2013676 (1992).","journal-title":"Ann. Neurol."},{"key":"802_CR48","first-page":"80","volume":"35","author":"E Bertrand","year":"1997","unstructured":"Bertrand, E., Lechowicz, W., Szpak, G. M. & Dymecki, J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson\u2019s disease. Folia Neuropathol. 35, 80\u201386 (1997).","journal-title":"Folia Neuropathol."},{"key":"802_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s004010000247","volume":"101","author":"E Braak","year":"2001","unstructured":"Braak, E. et al. \u03b1-Synuclein immunopositive Parkinson\u2019s disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 101, 195\u2013201 (2001).","journal-title":"Acta Neuropathol."},{"key":"802_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow, C., Lyness, S. A., Mortimer, J. A. & Chui, H. C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337\u2013341 (2003).","journal-title":"Arch. Neurol."},{"key":"802_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus, W. & Jellinger, K. The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease. J. Neuropathol. Exp. Neurol. 50, 743\u2013755 (1991).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"802_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"802_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jnc.15371","volume":"158","author":"DS Goldstein","year":"2021","unstructured":"Goldstein, D. S. et al. Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. J. Neurochem. 158, 554\u2013568 (2021).","journal-title":"J. Neurochem."},{"key":"802_CR54","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/mds.28615","volume":"36","author":"B Huynh","year":"2021","unstructured":"Huynh, B., Fu, Y., Kirik, D., Shine, J. M. & Halliday, G. M. Comparison of locus coeruleus pathology with nigral and forebrain pathology in Parkinson\u2019s disease. Mov. Disord. 36, 2085\u20132093 (2021).","journal-title":"Mov. Disord."},{"key":"802_CR55","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","volume":"259","author":"A Antonini","year":"2012","unstructured":"Antonini, A. et al. The progression of non-motor symptoms in Parkinson\u2019s disease and their contribution to motor disability and quality of life. J. Neurol. 259, 2621\u20132631 (2012).","journal-title":"J. Neurol."},{"key":"802_CR56","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","volume":"72","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad, S. M. et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 72, 863\u2013873 (2015).","journal-title":"JAMA Neurol."},{"key":"802_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-022-00289-y","volume":"11","author":"R Isonaka","year":"2022","unstructured":"Isonaka, R., Sullivan, P. & Goldstein, D. S. Pathophysiological significance of increased \u03b1-synuclein deposition in sympathetic nerves in Parkinson\u2019s disease: a post-mortem observational study. Transl. Neurodegener. 11, 15 (2022).","journal-title":"Transl. Neurodegener."},{"key":"802_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/practneurol-2013-000741","volume":"14","author":"A Todorova","year":"2014","unstructured":"Todorova, A., Jenner, P. & Chaudhuri, K. R. Non-motor Parkinson\u2019s: integral to motor Parkinson\u2019s, yet often neglected. Pract. Neurol. 14, 310\u2013322 (2014).","journal-title":"Pract. Neurol."},{"key":"802_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mds.27867","volume":"35","author":"DG Coughlin","year":"2020","unstructured":"Coughlin, D. G., Hurtig, H. I. & Irwin, D. J. Pathological influences on clinical heterogeneity in Lewy body diseases. Mov. Disord. 35, 5\u201319 (2020).","journal-title":"Mov. Disord."},{"key":"802_CR60","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.neuroimage.2017.07.045","volume":"168","author":"N Priovoulos","year":"2018","unstructured":"Priovoulos, N. et al. High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T. Neuroimage 168, 427\u2013436 (2018).","journal-title":"Neuroimage"},{"key":"802_CR61","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1093\/brain\/awz193","volume":"142","author":"MJ Betts","year":"2019","unstructured":"Betts, M. J. et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 142, 2558\u20132571 (2019).","journal-title":"Brain"},{"key":"802_CR62","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/brain\/awt152","volume":"136","author":"D Garc\u00eda-Lorenzo","year":"2013","unstructured":"Garc\u00eda-Lorenzo, D. et al. The coeruleus\/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson\u2019s disease. Brain 136, 2120\u20132129 (2013).","journal-title":"Brain"},{"key":"802_CR63","doi-asserted-by":"publisher","first-page":"105295","DOI":"10.1016\/j.nbd.2021.105295","volume":"152","author":"MB Kinnerup","year":"2021","unstructured":"Kinnerup, M. B. et al. Preserved noradrenergic function in Parkinson\u2019s disease patients with rest tremor. Neurobiol. Dis. 152, 105295 (2021).","journal-title":"Neurobiol. Dis."},{"key":"802_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/brain\/awx348","volume":"141","author":"M Sommerauer","year":"2018","unstructured":"Sommerauer, M. et al. Evaluation of the noradrenergic system in Parkinson\u2019s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 141, 496\u2013504 (2018).","journal-title":"Brain"},{"key":"802_CR65","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case\u2013control study. Lancet Neurol. 17, 618\u2013628 (2018).","journal-title":"Lancet Neurol."},{"key":"802_CR66","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case\u2013control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"802_CR67","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awab236","volume":"144","author":"CEJ Doppler","year":"2021","unstructured":"Doppler, C. E. J. et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson\u2019s disease. Brain 144, 2732\u20132744 (2021).","journal-title":"Brain"},{"key":"802_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab040","author":"CEJ Doppler","year":"2021","unstructured":"Doppler, C. E. J. et al. Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson\u2019s disease. Sleep https:\/\/doi.org\/10.1093\/sleep\/zsab040 (2021).","journal-title":"Sleep"},{"key":"802_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29072","author":"R Ye","year":"2022","unstructured":"Ye, R. et al. Locus coeruleus integrity from 7\u2009T MRI relates to apathy and cognition in parkinsonian disorders. Mov. Disord. https:\/\/doi.org\/10.1002\/mds.29072 (2022).","journal-title":"Mov. Disord."},{"key":"802_CR70","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.28945","volume":"37","author":"CF Madelung","year":"2022","unstructured":"Madelung, C. F. et al. Locus coeruleus shows a spatial pattern of structural disintegration in Parkinson\u2019s disease. Mov. Disord. 37, 479\u2013489 (2022).","journal-title":"Mov. Disord."},{"key":"802_CR71","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/mds.28859","volume":"37","author":"A Janzen","year":"2022","unstructured":"Janzen, A. et al. Rapid eye movement sleep behavior disorder: abnormal cardiac image and progressive abnormal metabolic brain pattern. Mov. Disord. 37, 624\u2013629 (2022).","journal-title":"Mov. Disord."},{"key":"802_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jnnp.2004.037028","volume":"76","author":"H Nagayama","year":"2005","unstructured":"Nagayama, H., Hamamoto, M., Ueda, M., Nagashima, J. & Katayama, Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 76, 249\u2013251 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"802_CR73","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM199703063361004","volume":"336","author":"DS Goldstein","year":"1997","unstructured":"Goldstein, D. S., Holmes, C., Cannon, R. O. III, Eisenhofer, G. & Kopin, I. J. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 336, 696\u2013702 (1997).","journal-title":"N. Engl. J. Med."},{"key":"802_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2004.02.018","volume":"220","author":"S Saiki","year":"2004","unstructured":"Saiki, S. et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J. Neurol. Sci. 220, 105\u2013111 (2004).","journal-title":"J. Neurol. Sci."},{"key":"802_CR75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10286-018-0547-6","volume":"28","author":"DS Goldstein","year":"2018","unstructured":"Goldstein, D. S. & Cheshire, W. P. Jr Roles of cardiac sympathetic neuroimaging in autonomic medicine. Clin. Auton. Res. 28, 397\u2013410 (2018).","journal-title":"Clin. Auton. Res."},{"key":"802_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.23455","volume":"26","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M. & Stevens, C. H. Glia: initiators and progressors of pathology in Parkinson\u2019s disease. Mov. Disord. 26, 6\u201317 (2011).","journal-title":"Mov. Disord."},{"key":"802_CR77","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1212\/WNL.0b013e3182a6cbd5","volume":"81","author":"B Mollenhauer","year":"2013","unstructured":"Mollenhauer, B. et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81, 1226\u20131234 (2013).","journal-title":"Neurology"},{"key":"802_CR78","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/npjparkd.2015.13","volume":"1","author":"P Zis","year":"2015","unstructured":"Zis, P., Erro, R., Walton, C. C., Sauerbier, A. & Chaudhuri, K. R. The range and nature of non-motor symptoms in drug-naive Parkinson\u2019s disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis. 1, 15013 (2015).","journal-title":"NPJ Parkinsons Dis."},{"key":"802_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.26077","volume":"30","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer, C. et al. The onset of nonmotor symptoms in Parkinson\u2019s disease (the ONSET PD study). Mov. Disord. 30, 229\u2013237 (2015).","journal-title":"Mov. Disord."},{"key":"802_CR80","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mds.23346","volume":"26","author":"SM van Rooden","year":"2011","unstructured":"van Rooden, S. M. et al. Clinical subtypes of Parkinson\u2019s disease. Mov. Disord. 26, 51\u201358 (2011).","journal-title":"Mov. Disord."},{"key":"802_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03118-w","volume":"11","author":"F Rodriguez-Sanchez","year":"2021","unstructured":"Rodriguez-Sanchez, F. et al. Identifying Parkinson\u2019s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. Sci. Rep. 11, 23645 (2021).","journal-title":"Sci. Rep."},{"key":"802_CR82","unstructured":"MacQueen, J.B. Some methods for classification and analysis of multivariate observations. In Proc. Fifth Berkeley Symposium on Mathematical Statistics and Probability (eds Le Cam, L. M. & Neyman, J.) 281\u2013297 (Univ. California Press, 1967)."},{"key":"802_CR83","unstructured":"Lazarsfeld, P. F. & Henry, N. W. in The American Soldier vol. 4: Measurement and Prediction (Houghton Mifflin, 1968)."},{"key":"802_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2307\/2981629","volume":"150","author":"AD Gordon","year":"1987","unstructured":"Gordon, A. D. A review of hierarchical classification. J. R. Stat. Soc. A 150, 119\u2013137 (1987).","journal-title":"J. R. Stat. Soc. A"},{"key":"802_CR85","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tins.2013.06.007","volume":"36","author":"JD Warren","year":"2013","unstructured":"Warren, J. D. et al. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci. 36, 561\u2013569 (2013).","journal-title":"Trends Neurosci."},{"key":"802_CR86","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1353-8020(11)70011-6","volume":"18","author":"WD van de Berg","year":"2012","unstructured":"van de Berg, W. D. et al. Patterns of \u03b1-synuclein pathology in incidental cases and clinical subtypes of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 18, S28\u2013S30 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"802_CR87","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mds.26605","volume":"31","author":"CH Adler","year":"2016","unstructured":"Adler, C. H. & Beach, T. G. Neuropathological basis of nonmotor manifestations of Parkinson\u2019s disease. Mov. Disord. 31, 1114\u20131119 (2016).","journal-title":"Mov. Disord."},{"key":"802_CR88","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/mds.20362","volume":"20","author":"JE Ahlskog","year":"2005","unstructured":"Ahlskog, J. E. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson\u2019s disease. Mov. Disord. 20, 271\u2013282 (2005).","journal-title":"Mov. Disord."},{"key":"802_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88651-4","volume":"11","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen, D. J. et al. Cross-sectional analysis of the Parkinson\u2019s Disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci. Rep. 11, 9611 (2021).","journal-title":"Sci. Rep."},{"key":"802_CR90","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","volume":"132","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray, C. H. et al. The distinct cognitive syndromes of Parkinson\u2019s disease: 5 year follow-up of the Campaign cohort. Brain 132, 2958\u20132969 (2009).","journal-title":"Brain"},{"key":"802_CR91","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D. et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov. Disord. 30, 919\u2013927 (2015).","journal-title":"Mov. Disord."},{"key":"802_CR92","doi-asserted-by":"publisher","first-page":"15015","DOI":"10.1038\/npjparkd.2015.15","volume":"1","author":"JY Szeto","year":"2015","unstructured":"Szeto, J. Y. et al. The relationships between mild cognitive impairment and phenotype in Parkinson\u2019s disease. NPJ Parkinsons Dis. 1, 15015 (2015).","journal-title":"NPJ Parkinsons Dis."},{"key":"802_CR93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Prim. 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"802_CR94","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.parkreldis.2014.02.010","volume":"20","author":"Y Mizutani","year":"2014","unstructured":"Mizutani, Y. et al. Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 520\u2013524 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"802_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2016.01.020","volume":"362","author":"JS Kim","year":"2016","unstructured":"Kim, J. S. et al. Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder. J. Neurol. Sci. 362, 59\u201363 (2016).","journal-title":"J. Neurol. Sci."},{"key":"802_CR96","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos, A. et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat. Disord. 20, 1231\u20131235 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"802_CR97","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1212\/WNL.0000000000002086","volume":"85","author":"DS Goldstein","year":"2015","unstructured":"Goldstein, D. S., Holmes, C., Sharabi, Y. & Wu, T. Survival in synucleinopathies: a prospective cohort study. Neurology 85, 1554\u20131561 (2015).","journal-title":"Neurology"},{"key":"802_CR98","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ana.24877","volume":"81","author":"H Kaufmann","year":"2017","unstructured":"Kaufmann, H. et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann. Neurol. 81, 287\u2013297 (2017).","journal-title":"Ann. Neurol."},{"key":"802_CR99","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/mds.28493","volume":"36","author":"C Fearon","year":"2021","unstructured":"Fearon, C., Lang, A. E. & Espay, A. J. The logic and pitfalls of Parkinson\u2019s disease as \u201cbrain-first\u201d versus \u201cbody-first\u201d subtypes. Mov. Disord. 36, 594\u2013598 (2021).","journal-title":"Mov. Disord."},{"key":"802_CR100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12640-014-9482-z","volume":"27","author":"SB Ross","year":"2015","unstructured":"Ross, S. B. & Stenfors, C. DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action. Neurotox. Res. 27, 15\u201330 (2015).","journal-title":"Neurotox. Res."},{"key":"802_CR101","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1046\/j.1460-9568.2003.02684.x","volume":"17","author":"J Srinivasan","year":"2003","unstructured":"Srinivasan, J. & Schmidt, W. J. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur. J. Neurosci. 17, 2586\u20132592 (2003).","journal-title":"Eur. J. Neurosci."},{"key":"802_CR102","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fncel.2018.00241","volume":"12","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Investigation of behavioral dysfunctions induced by monoamine depletions in a mouse model of Parkinson\u2019s disease. Front. Cell Neurosci. 12, 241 (2018).","journal-title":"Front. Cell Neurosci."},{"key":"802_CR103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JPD-2012-12076","volume":"2","author":"N Schintu","year":"2012","unstructured":"Schintu, N., Zhang, X. & Svenningsson, P. Studies of depression-related states in animal models of Parkinsonism. J. Parkinsons Dis. 2, 87\u2013106 (2012).","journal-title":"J. Parkinsons Dis."},{"key":"802_CR104","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.nbd.2011.10.023","volume":"45","author":"C Delaville","year":"2012","unstructured":"Delaville, C. et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol. Dis. 45, 763\u2013773 (2012).","journal-title":"Neurobiol. Dis."},{"key":"802_CR105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12402-012-0076-4","volume":"4","author":"J Hauser","year":"2012","unstructured":"Hauser, J., Sontag, T. A., Tucha, O. & Lange, K. W. The effects of the neurotoxin DSP4 on spatial learning and memory in Wistar rats. ADHD Atten. Deficit Hyperactivity Disord. 4, 93\u201399 (2012).","journal-title":"ADHD Atten. Deficit Hyperactivity Disord."},{"key":"802_CR106","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.bbi.2019.06.034","volume":"81","author":"S Song","year":"2019","unstructured":"Song, S. et al. Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor\/motor functions. Brain Behav. Immun. 81, 374\u2013387 (2019).","journal-title":"Brain Behav. Immun."},{"key":"802_CR107","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphar.2020.00435","volume":"11","author":"E Paredes-Rodriguez","year":"2020","unstructured":"Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P. & Miguelez, C. The noradrenergic system in Parkinson\u2019s disease. Front. Pharmacol. 11, 435 (2020).","journal-title":"Front. Pharmacol."},{"key":"802_CR108","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","volume":"5","author":"C Delaville","year":"2011","unstructured":"Delaville, C., Deurwaerd\u00e8re, P. D. & Benazzouz, A. Noradrenaline and Parkinson\u2019s disease. Front. Syst. Neurosci. 5, 31 (2011).","journal-title":"Front. Syst. Neurosci."},{"key":"802_CR109","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1093\/brain\/awac085","volume":"145","author":"MW Kucharczyk","year":"2022","unstructured":"Kucharczyk, M. W., Di Domenico, F. & Bannister, K. Distinct brainstem to spinal cord noradrenergic pathways inversely regulate spinal neuronal activity. Brain 145, 2293\u20132300 (2022).","journal-title":"Brain"},{"key":"802_CR110","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet, M. F. et al. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (\u201cLine 61\u201d) mice. Neurotherapeutics 9, 297\u2013314 (2012).","journal-title":"Neurotherapeutics"},{"key":"802_CR111","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JPD-140374","volume":"4","author":"KA McDowell","year":"2014","unstructured":"McDowell, K. A., Shin, D., Roos, K. P. & Chesselet, M. F. Sleep dysfunction and EEG alterations in mice overexpressing \u03b1-synuclein. J. Parkinsons Dis. 4, 531\u2013539 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"802_CR112","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nbd.2012.04.009","volume":"47","author":"PJ Hallett","year":"2012","unstructured":"Hallett, P. J., McLean, J. R., Kartunen, A., Langston, J. W. & Isacson, O. \u03b1-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol. Dis. 47, 258\u2013267 (2012).","journal-title":"Neurobiol. Dis."},{"key":"802_CR113","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.neurobiolaging.2008.11.010","volume":"31","author":"E Sotiriou","year":"2010","unstructured":"Sotiriou, E., Vassilatis, D. K., Vila, M. & Stefanis, L. Selective noradrenergic vulnerability in \u03b1-synuclein transgenic mice. Neurobiol. Aging 31, 2103\u20132114 (2010).","journal-title":"Neurobiol. Aging"},{"key":"802_CR114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-018-0541-1","volume":"6","author":"MT Henrich","year":"2018","unstructured":"Henrich, M. T. et al. A53T-\u03b1-synuclein overexpression in murine locus coeruleus induces Parkinson\u2019s disease-like pathology in neurons and glia. Acta Neuropathol. Commun. 6, 39 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"802_CR115","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1523\/JNEUROSCI.1468-19.2020","volume":"40","author":"LM Butkovich","year":"2020","unstructured":"Butkovich, L. M. et al. Transgenic mice expressing human \u03b1-synuclein in noradrenergic neurons develop locus ceruleus pathology and nonmotor features of Parkinson\u2019s disease. J. Neurosci. 40, 7559\u20137576 (2020).","journal-title":"J. Neurosci."},{"key":"802_CR116","first-page":"521","volume":"26","author":"MS Hunsley","year":"2003","unstructured":"Hunsley, M. S. & Palmiter, R. D. Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep 26, 521\u2013526 (2003).","journal-title":"Sleep"},{"key":"802_CR117","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641.e7 (2019).","journal-title":"Neuron"},{"key":"802_CR118","doi-asserted-by":"publisher","first-page":"e0263074","DOI":"10.1371\/journal.pone.0263074","volume":"17","author":"P Jovanovic","year":"2022","unstructured":"Jovanovic, P. et al. Sustained chemogenetic activation of locus coeruleus norepinephrine neurons promotes dopaminergic neuron survival in synucleinopathy. PLoS ONE 17, e0263074 (2022).","journal-title":"PLoS ONE"},{"key":"802_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228630","author":"FS Giorgi","year":"2020","unstructured":"Giorgi, F. S. et al. Locus coeruleus modulates neuroinflammation in parkinsonism and dementia. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21228630 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"802_CR120","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","volume":"29","author":"TN Taylor","year":"2009","unstructured":"Taylor, T. N. et al. Nonmotor symptoms of Parkinson\u2019s disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103\u20138113 (2009).","journal-title":"J. Neurosci."},{"key":"802_CR121","doi-asserted-by":"publisher","first-page":"175909142110097","DOI":"10.1177\/17590914211009730","volume":"13","author":"K Cui","year":"2021","unstructured":"Cui, K. et al. Restoration of noradrenergic function in Parkinson\u2019s disease model mice. ASN Neuro 13, 17590914211009730 (2021).","journal-title":"ASN Neuro"},{"key":"802_CR122","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.28999","volume":"37","author":"NL Taylor","year":"2022","unstructured":"Taylor, N. L. et al. The contribution of noradrenergic activity to anxiety-induced freezing of gait. Mov. Disord. 37, 1432\u20131443 (2022).","journal-title":"Mov. Disord."},{"key":"802_CR123","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/jpm12121994","volume":"12","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri, K. R., Titova, N., Qamar, M. A., Mur\u0103\u0219an, I. & Falup-Pecurariu, C. The dashboard vitals of Parkinson\u2019s: not to be missed yet an unmet need. J. Pers. Med. 12, 1994 (2022).","journal-title":"J. Pers. Med."},{"key":"802_CR124","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"key":"802_CR125","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.25857","volume":"29","author":"GM Halliday","year":"2014","unstructured":"Halliday, G. M., Leverenz, J. B., Schneider, J. S. & Adler, C. H. The neurobiological basis of cognitive impairment in Parkinson\u2019s disease. Mov. Disord. 29, 634\u2013650 (2014).","journal-title":"Mov. Disord."},{"key":"802_CR126","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI103850","volume":"38","author":"M Goodall","year":"1959","unstructured":"Goodall, M., Kirshner, N. & Rosen, L. Metabolism of noradrenaline in the human. J. Clin. Invest. 38, 707\u2013714 (1959).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00802-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:02:55Z","timestamp":1685952175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00802-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00802-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"16 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.C. declares that he has received honoraria for advisory board membership from 4D Pharma, AbbVie, Acadia, Britannia, Global kinetics (GKC), Lobsor, Profile Pharma, Roche, Scion, Stada, Synovion, Therevance, UCB and Zambon; speaker\u2019s honoraria for lectures from AbbVie, Bial, Boeringer Ingelheim, Britannia, Kyowa Kirin, Novartis, SK Pharma, UCB, and Zambon; investigator initiated research grants from AbbVie, Bial; Britannia, UCB, Global Kinetics; and academic grant funding from EU Horizon 2020, Parkinson\u2019s UK, Wellcome Trust, Kirby Laing Foundation and the Medical Research Council; royalty payments or license fees from Oxford University Press, and Cambridge University Press, MAPI institute (King\u2019s Parkinson Disease Pain Scale (KPPS) and Parkinson Disease Sleep Scale 2 (PDSS-2)); and payment for expert testimony from the General Medical Council unrelated to the submitted work. V.L. declares that she has received grants and\/or honoraria for speaker-related activities from Abbvie, Bial, Britannia Pharmaceuticals, Invisio, Profile and UCB unrelated to the submitted work. P.S. declares that he has received honoraria for advisory board membership from AbbVie, Kyowa Kirin and Takeda; honoraria for lectures from AbbVie and Zambon; and academic grants from, Lexa International\/Nordstjernan, Michael J. Fox Foundation, Stockholm City Council and Wallenberg Clinical Scholarship unrelated to the submitted work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}